Has the U.K. Biotech Industry valuation changed over the past few years?

Investors are more pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 38.3x which is lower than its 3-year average PE of 49.1x.

How does U.K. Biotech compare with similar industries?

There is insufficient data on the sub-industries of this industry.

U.K. (FTSE) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE
Sat, 28 May 2022	UK£7.0b	UK£1.1b	-UK£146,804,240.00	38.3x
Mon, 25 Apr 2022	UK£7.2b	UK£1.1b	-UK£91,620,330.00	37.9x
Wed, 23 Mar 2022	UK£7.4b	UK£1.1b	-UK£98,687,029.00	33x
Fri, 18 Feb 2022	UK£8.5b	UK£1.1b	-UK£119,732,737.00	35.3x
Sun, 16 Jan 2022	UK£9.7b	UK£1.1b	-UK£123,388,341.00	47.3x
Tue, 14 Dec 2021	UK£11.1b	UK£1.1b	-UK£121,180,343.00	54x
Thu, 11 Nov 2021	UK£11.9b	UK£1.1b	-UK£149,832,471.00	69.8x
Sat, 09 Oct 2021	UK£11.8b	UK£1.1b	-UK£148,479,118.00	68.8x
Mon, 06 Sep 2021	UK£12.9b	UK£1.1b	-UK£143,503,184.62	56.7x
Wed, 04 Aug 2021	UK£12.1b	UK£1.0b	-UK£172,541,949.91	29.6x
Sat, 08 May 2021	UK£11.5b	UK£1.0b	-UK£166,311,048.52	30.3x
Tue, 09 Feb 2021	UK£10.8b	UK£1.0b	-UK£143,994,708.81	33.3x
Mon, 02 Nov 2020	UK£9.0b	UK£985.1m	-UK£119,804,987.81	60x
Thu, 06 Aug 2020	UK£8.2b	UK£992.8m	-UK£138,646,257.45	54.3x
Sun, 10 May 2020	UK£7.1b	UK£985.7m	-UK£114,704,522.81	55.7x
Sat, 01 Feb 2020	UK£6.4b	UK£946.9m	-UK£63,951,543.44	51.5x
Tue, 05 Nov 2019	UK£5.7b	UK£925.3m	-UK£83,659,311.30	54.1x
Fri, 09 Aug 2019	UK£5.9b	UK£898.8m	-UK£94,660,524.01	59.6x


GB Market	1.04%
Healthcare	2.17%
Biotech	0.71%
Biotech	0.71%

Company	Last Price	7D	1Y	Valuation
ABC Abcam	UK£11.72	1.8% +UK£48.0m	-17.2%	PS609.1x
AVCT Avacta Group	UK£1.26	14.9% +UK£41.6m	-46.7%	PS109.2x
GNS Genus	UK£27.34	1.9% +UK£32.6m	-45.9%	PS48.2x
OXB Oxford Biomedica	UK£5.14	4.4% +UK£20.7m	-54.9%	PS26x
BVXP Bioventix	UK£37.75	5.6% +UK£10.4m	-6.8%	PS29.7x

May 18

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

Synairgen plc announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. SPRINTER (SG018; NCT04732949) was a global, randomised, placebo-controlled, double-blind clinical trial assessing the efficacy and safety of inhaled SNG001 for the treatment of adults hospitalised due to COVID-19 who required treatment with supplemental oxygen. The trial recruited a total of 623 patients who were randomised to receive SNG001 (n=309) or placebo (n=314) on top of standard of care (SOC). The data from this pivotal trial will be presented at the Clinical Trials Symposium of the American Thoracic Society 2022 (ATS 2022) International Conference, being held in San Francisco, California from 13-18 May 2022. A separate poster presentation is scheduled for 17 May 2022. Synairgen announced in February 2022 that the Phase 3 SPRINTER trial did not meet the primary endpoints of discharge from hospital and recovery. There was, however, an encouraging signal in reduction in the relative risk (RRR) of progression to severe disease or death within 35 days (25.7%1 reduction in the Intention-to-Treat population and 36.3% reduction in the Per Protocol population). To assess the strength of this signal and identify specific patient populations that might benefit most from treatment, post hoc analyses were performed on groups of patients recognised to be at greater risk of developing severe disease in hospital. These analyses included patients =65 years old, those with co-morbidities associated with worse COVID-19 outcomes, and those who, at baseline, despite receiving low flow oxygen, had clinical signs of compromised respiratory function (defined as oxygen saturation of = 92% or respiratory rate = 21 breaths/min). These analyses showed stronger treatment effects with SNG001 in these high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. In these patients, who represented approximately one-third of the SPRINTER trial population, SNG001 significantly reduced the risk of progression to severe disease and death compared to placebo by 70% in the Per Protocol population (Odds Ratio (95% Confidence Interval) 0.23 (0.06, 0.98); p=0.046). SNG001 was well tolerated in the SPRINTER trial with a favourable safety profile consistent with previous studies: The proportion of patients with any treatment-emergent adverse events (TEAE) related to study treatment was 22.6% for SNG001 vs. 25.4% for placebo. The proportion of patients with any serious TEAE was 12.6% for SNG001 vs. 18.2% for placebo. The proportion of patients with a serious respiratory3 TEAE was 4.7% for SNG001 vs. 9.9% for placebo.

May 17

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

PureTech Health plc announced the presentation of additional data for PureTech’s LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. The data were shared in a scientific poster session and detailed the outcomes of a study in healthy older adults showing that LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels. Key outcomes of this study that are supportive of the observed improved tolerability of LYT-100 were reported in January 2022. The data support the upcoming registration-enabling studies in which PureTech plans to investigate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF) at the planned 550 mg three times daily dose (TID) as well as a dose with a higher total drug exposure than the currently approved dose of pirfenidone to evaluate if higher exposure could translate into improved efficacy. Pirfenidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF but is associated with significant tolerability issues that LYT-100, as a deuterated form of pirfenidone, is intended to reduce. PureTech intends to advance LYT-100 into late-stage clinical development for the treatment of IPF using a 505(b)(2) development path, beginning with a dose-ranging study evaluating six months of treatment with LYT-100 with topline results expected by the end of 2023. The double-blind, randomized, crossover Phase 1 study evaluated the tolerability of LYT-100 550 mg TID versus pirfenidone 801 mg TID in 49 healthy older adults aged 60-79, an age group consistent with that of the IPF patient population. As previously announced, the study was supportive of an improved tolerability profile for LYT-100 with 38% fewer subjects treated with LYT-100 experiencing any AEs compared with those treated with pirfenidone (30.4% vs. 48.9%). The poster presented details the incidence of AEs in the study population including the reduction in incidence of AEs in LYT-100 vs. pirfenidone administration in both fed and fasted subjects. Notably, LYT-100 at 550 mg TID (fed state) dose met the criteria for bioequivalence for exposure compared to the FDA-approved dosage of pirfenidone – 801 mg TID – but with a lower Cmax. Higher dosages of LYT-100 may provide enhanced antifibrotic and anti-inflammatory activity.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

VRCI

Verici Dx plc, Annual General Meeting, Jun 27, 2022

GENF

Genflow Biosciences plc, Annual General Meeting, Jun 14, 2022

SNG

Synairgen Presents Detailed Analysis of Phase 3 Sprinter Trial Evaluating Sng001 in Hospitalised Covid-19 Patients At ATS 2022

ETX

e-therapeutics plc, Annual General Meeting, Jul 19, 2022

PRTC

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

FARN

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

OXB

Consensus forecasts updated

AVCT

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

4BB

Full year 2021 earnings: EPS and revenues exceed analyst expectations

ABC

Is Abcam (LON:ABC) A Risky Investment?

SBTX

SkinBioTherapeutics Plc Announces Appointment of Danielle Bekker as Non-Executive Director

ONC

Price target increased to UK£2.22

OKYO

High number of new and inexperienced directors

CIR

Price target increased to UK£0.46

BVXP

Price target increased to UK£43.00

GNS

Price target decreased to UK£46.05